Adage Capital Partners
SLN

Adage Capital Partners’s Silence Therapeutics SLN Stock Holding History

Adage Capital Partners’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-320,000
Closed -$5.82M – 954
2024
Q3 		$5.82M Sell
320,000
-280,000
-47% -$5.21M 0.01% 698
2024
Q2 		$11.4M Hold
600,000
– – 0.02% 573
2024
Q1 		$13M Buy
+600,000
New +$13M 0.02% 552
2023
Q1 		– Sell
-700,000
Closed -$10.7M – 984
2022
Q4 		$10.7M Hold
700,000
– – 0.03% 615
2022
Q3 		$7.03M Buy
700,000
+135,000
+24% +$1.42M 0.02% 727
2022
Q2 		$6.7M Buy
565,000
+15,000
+3% +$182K 0.02% 765
2022
Q1 		$10.4M Hold
550,000
– – 0.02% 681
2021
Q4 		$13.1M Buy
550,000
+105,556
+24% +$2.44M 0.02% 616
2021
Q3 		$9.16M Hold
444,444
– – 0.02% 714
2021
Q2 		$11.6M Hold
444,444
– – 0.02% 651
2021
Q1 		$10.2M Buy
+444,444
New +$10.8M 0.02% 666

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners's SLN Position: Q4 2024 in Review

Adage Capital Partners sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 320,000 shares — an estimated $5.82M sold.

Adage Capital Partners first reported a position in SLN in Q1 2021 and held it in 11 quarters. The position peaked at $13.1M in Q4 2021. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • Adage Capital Partners reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 320,000 Silence Therapeutics shares in Q4 2024, an estimated $5.82M.
  • Adage Capital Partners first reported a position in Silence Therapeutics in Q1 2021 and held it in 11 quarters.
  • Adage Capital Partners's Silence Therapeutics position peaked at $13.1M in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.